ArticleThe World Allergy Organization journal2026

Corrigendum to "Retrospective analysis of the efficacy and safety of 100 mg abrocitinib in patients with moderate to severe atopic dermatitis: Real-world study" [World Allergy Organ J 16 (2) (2023) 101167].

Maoying Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.